Table 4.

Changes in Visual Acuity, Subfoveal Choroidal Thickness, and Central Retinal Thickness During Intravitreal Aflibercept Injection Treatment for Neovascular Age-Related Macular Degeneration

	Baseline	3 Months	6 Months	9 Months	12 Months	Difference Between Baseline and 12 Months (95% CI)	P value*
BCVA, logMAR
Mean ± SD	0.40 ± 0.38	0.33 ± 0.41	0.32 ± 0.41	0.31 ± 0.42	0.29 ± 0.41	0.12 (0.05–0.17)	<0.001
Median	0.30	0.30	0.22	0.22	0.15
Subfoveal choroidal thickness (µm)
Mean ± SD	223 ± 90	193 ± 88	193 ± 88	189 ± 88	192 ± 88	30 (23–37)	<0.001
Median	210.5	167.5	166.5	171	177
Decrease from baseline (%)		13.4	13.7	15.1	13.7
Central retinal thickness (µm)
Mean ± SD	380 ± 180	202 ± 105	190 ± 85	190 ± 84	206 ± 119	174 (130–218)	<0.001
Median	338	174	164	170	172
Decrease from baseline (%)		46.9	49.9	50.1	45.8

Note: *Repeated measures ANOVA.

Abbreviations: CI, confidence interval; BCVA, best-corrected visual acuity; logMAR, logarithm of minimal angle of resolution; SD, standard deviation.